Search Results - "Foster, Julie M"

Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group by Campbell, Kevin, Gastier‐Foster, Julie M., Mann, Meegan, Naranjo, Arlene H., Ryn, Collin, Bagatell, Rochelle, Matthay, Katherine K., London, Wendy B., Irwin, Meredith S., Shimada, Hiroyuki, Granger, M. Meaghan, Hogarty, Michael D., Park, Julie R., DuBois, Steven G.

“…BACKGROUND High‐level MYCN amplification (MNA) is associated with poor outcome and unfavorable clinical and biological features in patients with neuroblastoma…”
Get full text

Recurrent DGCR8, DROSHA, and SIX Homeodomain Mutations in Favorable Histology Wilms Tumors by Walz, Amy L., Ooms, Ariadne, Gadd, Samantha, Gerhard, Daniela S., Smith, Malcolm A., Guidry Auvil, Jaime M., Meerzaman, Daoud, Chen, Qing-Rong, Hsu, Chih Hao, Yan, Chunhua, Nguyen, Cu, Hu, Ying, Bowlby, Reanne, Brooks, Denise, Ma, Yussanne, Mungall, Andrew J., Moore, Richard A., Schein, Jacqueline, Marra, Marco A., Huff, Vicki, Dome, Jeffrey S., Chi, Yueh-Yun, Mullighan, Charles G., Ma, Jing, Wheeler, David A., Hampton, Oliver A., Jafari, Nadereh, Ross, Nicole, Gastier-Foster, Julie M., Perlman, Elizabeth J.

“…We report the most common single-nucleotide substitution/deletion mutations in favorable histology Wilms tumors (FHWTs) to occur within SIX1/2 (7% of 534…”
Get full text

Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group by Irwin, Meredith S, Naranjo, Arlene, Zhang, Fan F, Cohn, Susan L, London, Wendy B, Gastier-Foster, Julie M, Ramirez, Nilsa C, Pfau, Ruthann, Reshmi, Shalini, Wagner, Elizabeth, Nuchtern, Jed, Asgharzadeh, Shahab, Shimada, Hiroyuki, Maris, John M, Bagatell, Rochelle, Park, Julie R, Hogarty, Michael D

“…Treatment planning for children with neuroblastoma requires accurate assessment of prognosis. The most recent Children's Oncology Group (COG) risk…”
Get full text

PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report by Skapek, Stephen X., Anderson, James, Barr, Frederic G., Bridge, Julia A., Gastier-Foster, Julie M., Parham, David M., Rudzinski, Erin R., Triche, Timothy, Hawkins, Douglas S.

“…Background Rhabdomyosarcoma (RMS) is divided into two major histological subtypes: alveolar (ARMS) and embryonal (ERMS), with most ARMS expressing one of two…”
Get full text

Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study by Moriyama, Takaya, MD, Metzger, Monika L, MD, Wu, Gang, PhD, Nishii, Rina, MS, Qian, Maoxiang, PhD, Devidas, Meenakshi, PhD, Yang, Wenjian, PhD, Cheng, Cheng, Prof, Cao, Xueyuan, PhD, Quinn, Emily, MS, Raimondi, Susana, Prof, Gastier-Foster, Julie M, Prof, Raetz, Elizabeth, Prof, Larsen, Eric, MD, Martin, Paul L, MD, Bowman, W Paul, MD, Winick, Naomi, Prof, Komada, Yoshihiro, Prof, Wang, Shuoguo, PhD, Edmonson, Michael, BA, Xu, Heng, PhD, Mardis, Elaine, Prof, Fulton, Robert, MS, Pui, Ching-Hon, Prof, Mullighan, Charles, Prof, Evans, William E, Prof, Zhang, Jinghui, Prof, Hunger, Stephen P, Prof, Relling, Mary V, Prof, Nichols, Kim E, Prof, Loh, Mignon L, Prof, Yang, Jun J, Dr

“…Summary Background Hereditary predisposition is rarely suspected for childhood acute lymphoblastic leukaemia (ALL). Recent reports of germline ETV6 variations…”
Get full text

Isolated late testicular relapse of B‐cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response‐based testicular radiation: A Children's Oncology Group study by Barredo, Julio C., Hastings, Caroline, Lu, Xiamin, Devidas, Meenakshi, Chen, Yichen, Armstrong, Daniel, Winick, Naomi, Wood, Brent Lee, Yanofsky, Rochelle, Loh, Mignon, Gastier‐Foster, Julie M., Jorstad, Dean Thomas, Marcus, Robert, Ritchey, Kim, Carrol, William L., Hunger, Stephen P.

“…Background The incidence of isolated testicular relapse (ITR) of acute lymphoblastic leukemia (ALL) has decreased with contemporary treatment strategies, but…”
Get full text

Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group by Rudzinski, Erin R., Anderson, James R., Chi, Yueh‐Yun, Gastier‐Foster, Julie M., Astbury, Caroline, Barr, Frederic G., Skapek, Stephen X., Hawkins, Douglas S., Weigel, Brenda J., Pappo, Alberto, Meyer, William H., Arnold, Michael A., Teot, Lisa A., Parham, David M.

“…Background Distinguishing alveolar rhabdomyosarcoma (ARMS) from embryonal rhabdomyosarcoma (ERMS) has historically been of prognostic and therapeutic…”
Get full text

IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients by Pulsipher, Michael A., Carlson, Chris, Langholz, Bryan, Wall, Donna A., Schultz, Kirk R., Bunin, Nancy, Kirsch, Ilan, Gastier-Foster, Julie M., Borowitz, Michael, Desmarais, Cindy, Williamson, David, Kalos, Michael, Grupp, Stephan A.

“…Positive detection of minimal residual disease (MRD) by multichannel flow cytometry (MFC) prior to hematopoietic cell transplantation (HCT) of patients with…”
Get full text

Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232 by Borowitz, Michael J., Wood, Brent L., Devidas, Meenakshi, Loh, Mignon L., Raetz, Elizabeth A., Salzer, Wanda L., Nachman, James B., Carroll, Andrew J., Heerema, Nyla A., Gastier-Foster, Julie M., Willman, Cheryl L., Dai, Yunfeng, Winick, Naomi J., Hunger, Stephen P., Carroll, William L., Larsen, Eric

“…Minimal residual disease (MRD) is highly prognostic in pediatric B-precursor acute lymphoblastic leukemia (B-ALL). In Children's Oncology Group high-risk B-ALL…”
Get full text

A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor by Gadd, Samantha, Huff, Vicki, Walz, Amy L, Ooms, Ariadne H A G, Armstrong, Amy E, Gerhard, Daniela S, Smith, Malcolm A, Auvil, Jaime M Guidry, Meerzaman, Daoud, Chen, Qing-Rong, Hsu, Chih Hao, Yan, Chunhua, Nguyen, Cu, Hu, Ying, Hermida, Leandro C, Davidsen, Tanja, Gesuwan, Patee, Ma, Yussanne, Zong, Zusheng, Mungall, Andrew J, Moore, Richard A, Marra, Marco A, Dome, Jeffrey S, Mullighan, Charles G, Ma, Jing, Wheeler, David A, Hampton, Oliver A, Ross, Nicole, Gastier-Foster, Julie M, Arold, Stefan T, Perlman, Elizabeth J

“…Elizabeth Perlman and colleagues use genome-wide sequencing, RNA expression, DNA copy number and methylation analyses to characterize the genomic landscape of…”
Get full text

Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group by Reshmi, Shalini C., Harvey, Richard C., Roberts, Kathryn G., Stonerock, Eileen, Smith, Amy, Jenkins, Heather, Chen, I-Ming, Valentine, Marc, Liu, Yu, Li, Yongjin, Shao, Ying, Easton, John, Payne-Turner, Debbie, Gu, Zhaohui, Tran, Thai Hoa, Nguyen, Jonathan V., Devidas, Meenakshi, Dai, Yunfeng, Heerema, Nyla A., Carroll, Andrew J., Raetz, Elizabeth A., Borowitz, Michael J., Wood, Brent L., Angiolillo, Anne L., Burke, Michael J., Salzer, Wanda L., Zweidler-McKay, Patrick A., Rabin, Karen R., Carroll, William L., Zhang, Jinghui, Loh, Mignon L., Mullighan, Charles G., Willman, Cheryl L., Gastier-Foster, Julie M., Hunger, Stephen P.

“…Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a high-risk subtype characterized by genomic alterations that activate cytokine…”
Get full text

Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D by Mendell, Jerry R., Rodino-Klapac, Louise R., Rosales, Xiomara Q., Coley, Brian D., Galloway, Gloria, Lewis, Sarah, Malik, Vinod, Shilling, Chris, Byrne, Barry J., Conlon, Thomas, Campbell, Katherine J., Bremer, William G., Taylor, Laura E., Flanigan, Kevin M., Gastier-Foster, Julie M., Astbury, Caroline, Kota, Janaiah, Sahenk, Zarife, Walker, Christopher M., Clark, K. Reed

“…Objective: The aim of this study was to attain long‐lasting alpha‐sarcoglycan gene expression in limb‐girdle muscular dystrophy, type 2D (LGMD2D) subjects…”
Get full text

Genome‐wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients by Koster, Roelof, Panagiotou, Orestis A., Wheeler, William A., Karlins, Eric, Gastier‐Foster, Julie M., Caminada de Toledo, Silvia Regina, Petrilli, Antonio S., Flanagan, Adrienne M., Tirabosco, Roberto, Andrulis, Irene L., Wunder, Jay S., Gokgoz, Nalan, Patiño‐Garcia, Ana, Lecanda, Fernando, Serra, Massimo, Hattinger, Claudia, Picci, Piero, Scotlandi, Katia, Thomas, David M., Ballinger, Mandy L., Gorlick, Richard, Barkauskas, Donald A., Spector, Logan G., Tucker, Margaret, Belynda, D. Hicks, Yeager, Meredith, Hoover, Robert N., Wacholder, Sholom, Chanock, Stephen J., Savage, Sharon A., Mirabello, Lisa

“…Survival rates for osteosarcoma, the most common primary bone cancer, have changed little over the past three decades and are particularly low for patients…”
Get full text

Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Oncology Group by Wang, Larry L., Suganuma, Rie, Ikegaki, Naohiko, Tang, Xao, Naranjo, Arlene, McGrady, Patrick, London, Wendy B., Hogarty, Michael D., Gastier‐Foster, Julie M., Look, A. Thomas, Park, Julie R., Maris, John M., Cohn, Susan L., Seeger, Robert C., Shimada, Hiroyuki

“…BACKGROUND This study sought to investigate biological/clinicopathological characteristics of neuroblastoma, undifferentiated subtype (NBUD). METHODS This…”
Get full text

Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia by Oshima, Koichi, Khiabanian, Hossein, da Silva-Almeida, Ana C., Tzoneva, Gannie, Abate, Francesco, Ambesi-Impiombato, Alberto, Sanchez-Martin, Marta, Carpenter, Zachary, Penson, Alex, Perez-Garcia, Arianne, Eckert, Cornelia, Nicolas, Concepción, Balbin, Milagros, Sulis, Maria Luisa, Kato, Motohiro, Koh, Katsuyoshi, Paganin, Maddalena, Basso, Giuseppe, Gastier-Foster, Julie M., Devidas, Meenakshi, Loh, Mignon L., Kirschner-Schwabe, Renate, Palomero, Teresa, Rabadan, Raul, Ferrando, Adolfo A.

“…Although multiagent combination chemotherapy is curative in a significant fraction of childhood acute lymphoblastic leukemia (ALL) patients, 20% of cases…”
Get full text

TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children by Qian, Maoxiang, Cao, Xueyuan, Devidas, Meenakshi, Yang, Wenjian, Cheng, Cheng, Dai, Yunfeng, Carroll, Andrew, Heerema, Nyla A, Zhang, Hui, Moriyama, Takaya, Gastier-Foster, Julie M, Xu, Heng, Raetz, Elizabeth, Larsen, Eric, Winick, Naomi, Bowman, W Paul, Martin, Paul L, Mardis, Elaine R, Fulton, Robert, Zambetti, Gerard, Borowitz, Michael, Wood, Brent, Nichols, Kim E, Carroll, William L, Pui, Ching-Hon, Mullighan, Charles G, Evans, William E, Hunger, Stephen P, Relling, Mary V, Loh, Mignon L, Yang, Jun J

“…Purpose Germline TP53 variation is the genetic basis of Li-Fraumeni syndrome, a highly penetrant cancer predisposition condition. Recent reports of germline…”
Get full text

Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group by Arnold, Michael A., Anderson, James R., Gastier-Foster, Julie M., Barr, Frederic G., Skapek, Stephen X., Hawkins, Douglas S., Raney Jr, R. Beverly, Parham, David M., Teot, Lisa A., Rudzinski, Erin R., Walterhouse, David O.

“…Background Distinguishing alveolar rhabdomyosarcoma (ARMS) from embryonal rhabdomyosarcoma (ERMS) is of prognostic and therapeutic importance. Criteria for…”
Get full text

Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434 by Winter, Stuart S., Dunsmore, Kimberly P., Devidas, Meenakshi, Eisenberg, Nancy, Asselin, Barbara L., Wood, Brent L., Leonard RN, Marcia S., Murphy, John, Gastier-Foster, Julie M., Carroll, Andrew J., Heerema, Nyla A., Loh, Mignon L., Raetz, Elizabeth A., Winick, Naomi J., Carroll, William L., Hunger, Stephen P.

“…Background Nelarabine has shown impressive single agent clinical activity in T‐cell acute lymphoblastic leukemia (T‐ALL), but has been associated with…”
Get full text

Expanding the spectrum of CEP55‐associated disease to viable phenotypes by Barrie, Elizabeth S., Overwater, Eline, Haelst, Mieke M., Motazacker, M. Mahdi, Truxal, Kristen V., Crist, Erin, Mostafavi, Roya, Pivnick, Eniko K., Choudhri, Asim F., Narumanchi, TaraChandra, Castelluccio, Valerie, Walsh, Laurence E., Garganta, Cheryl, Gastier‐Foster, Julie M.

“…Homozygosity for nonsense variants in CEP55 has been associated with a lethal condition characterized by multinucleated neurons, anhydramnios, renal dysplasia,…”
Get full text

Homozygous variants in AMPD2 and COL11A1 lead to a complex phenotype of pontocerebellar hypoplasia type 9 and Stickler syndrome type 2 by Abreu, Nicolas J., Koboldt, Daniel C., Gastier‐Foster, Julie M., Dave‐Wala, Ashita, Flanigan, Kevin M., Waldrop, Megan A.

“…Pontocerebellar hypoplasia type 9 (PCH9) is an autosomal recessive neurodevelopmental disorder caused by pathogenic variants in the AMPD2 gene. We evaluated…”
Get full text